Browse by Vaccine Type

This page shows data for DNA based vaccine vaccine type.
Total Entries Retrieved: 29
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10065 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Approved Zydus Candila Healthcare Limited 2021 India 12 years and above NA Intradermal NA SARS CoV-2 envelope protein NA DCGI NA India NA NA NA https://pib.gov.in/PressReleasePage.aspx?PRID=1747669#:~:text=Zydus%20Cadila%20has%20received%20approval,adults%2012%20years%20and%20above. NA
10101 ENGERIX-B Hepatitis B Hepatitic Hepatitis B virus double stranded DNA DNA based vaccine Approved GlaxoSmithKline NA Rixensart, Belgium All age group 3 doses at regimen of 0, 1, and 6 months Intramuscular NA HBsAg NA US FDA NA NA NA NA NA https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ https://www.fda.gov/vaccines-blood-biologics/vaccines/engerix-b
10150 Covigenix VAX-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Entos Pharmaceuticals Inc. 2020 Canada 18 - 85 years 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus Fusogenix PLV NA Canadian Institutes of Health Research NA NA NA NCT04591184 https://clinicaltrials.gov/ct2/show/NCT04591184 https://clinicaltrials.gov/ct2/history/NCT04591184
10152 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA 18 - 59 years NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 32585611 NCT04334980 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10164 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA NA Single dose Oral NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10167 CORVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services NA NA NA 2 doses 14 days apart Intradermal NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10168 Covigenix VAX-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Entos Pharmaceuticals Inc. 2021 Canada NA 2 doses 14 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10186 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation 2020 Australia 18 years and above NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04334980 https://clinicaltrials.gov/show/NCT04334980 NA
10193 CORVax12 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services, OncoSec Medical Inc. 2021 USA 18 years and above NA Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04627675 https://clinicaltrials.gov/ct2/show/NCT04627675 NA
10199 VRC-SRSDNA015-00-VP SARS Respiratory SARS-CoV positive-sense, single-stranded RNA DNA based vaccine Phase 1 National Institute of Allergy and Infectious Diseases 2017 USA 18 - 50 years NA Intramuscular NA SARS CoV spike glycoprotein NA NA NA NA NA 33341119 NCT00099463 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10201 DNA Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA DNA based vaccine Phase 1 National Institute of Health 2003 USA 18 - 44 years NA NA NA NA NA NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT00072605 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10219 dMAb Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 NA NA NA NA NA Intramuscular NA CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10220 pCHIKV-7 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 NA NA NA NA NA NA NA cDNA of 181/25 NA NA NA NA NA 31921059 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930866/ NA
10253 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Cadila Healthcare Ltd NA NA NA 3 doses on day 0, 28 and 56 Intradermal NA NA NA NA NA NA nCov vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10254 GX-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Genexine Consortium 2021 South Korea 18 - 55 years 2 doses 28 days apart Intramuscular NA SARS-CoV-2 S-protein antigen including the Nucleocapsid protein antigen NA NA NA NA NA 33816047 NCT04715997 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10274 COVID-eVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Takis, Rottapharm Biotech 2021 Italy 18 - 65 years 2 doses 4 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04788459 https://clinicaltrials.gov/show/NCT04788459 NA
10282 GLS-5310 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2021 South Korea 19 - 65 years 2 doses 28 days apart Intradermal NA NA NA NA NA NA NA NA NCT04673149 https://clinicaltrials.gov/show/NCT04673149 NA
10289 AG0302-COVID19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 AnGes Inc. 2021 Japan 18 years and above 3 doses 2 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04993586 https://clinicaltrials.gov/ct2/show/NCT04993586 NA
10293 GLS-5300 (INO-4700) MERS Respiratory MERS-CoV positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2020 South Korea 19 - 70 years 3 doses Intradermal NA MERS CoV spike glycoprotein NA NA Inovio Pharmaceuticals, International Vaccine Institute NA GLS-5300 NA NCT03721718 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10325 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.isrctn.com/ISRCTN15779782
10333 AG0301-COVID19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 AnGes Inc. 2021 Japan 18 years and above 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Japan Agency for Medical Research and Development NA NA 33816047 NCT04655625 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10373 PENN CHIKV-2008 (PC-08) Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 University of Pennsylvania 2011 USA NA NA NA NA CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA NA NA https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019110/
10396 pMCE321 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA Intramuscular NA Sequence of E3, E2, and E1 genes under a CMV promoter NA NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10397 iDNA Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA Intramuscular NA CHIKV strain 181/25 NA NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10398 DREP-Env Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA Intradermal NA CHIKV replicon (nsP1 to nsP4) and CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10415 p181/25-7 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA NA NA CHIKV strain 181/25 NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10416 CVM1-IgG Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA NA NA E2-reactive monoclonal antibody NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10417 pVax1-MCE321 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA NA NA CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10418 DREP-Env Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA Intradermal NA DNA replicon encoding nsP and E1, E2, E3 NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA